T-cell receptor-CD3 complex and peptide-Major Histocompatibility Complex (TCR-CD3-pMHC) (TCR-CD3-pMHC)

The T-cell receptor-CD3 complex and peptide-Major Histocompatibility Complex (TCR-CD3-pMHC) interaction is the fundamental unit of antigen recognition in the adaptive immune system [1]. This multi-protein assembly forms when a T-cell receptor (TCR), associated with CD3 signaling subunits (gamma, delta, epsilon, and zeta), binds to a specific peptide presented by a Major Histocompatibility Complex (MHC) molecule on an antigen-presenting cell or a target cell [2, 5]. This recognition event triggers intracellular signaling cascades that lead to T-cell activation, proliferation, and the execution of effector functions such as cytokine release and direct cell-mediated cytotoxicity [1]. In oncology, this complex is a primary target for bispecific T-cell engagers (BiTEs) and Immune Mobilizing Monoclonal TCRs Against Cancer (ImmTACs), which physically bridge T-cells to tumor cells to induce a potent anti-tumor response [3, 4]. Conversely, monoclonal antibodies targeting the CD3 component are utilized as immunosuppressants to prevent organ transplant rejection or treat autoimmune conditions by modulating T-cell receptor signaling [5]. The therapeutic use of agents targeting this complex requires careful monitoring for systemic inflammatory toxicities, such as cytokine release syndrome, and often involves patient selection based on HLA genotype [3, 4].

Other names

Immunological synapseTCR-pMHC complexCD3-TCR-MHC interactionAntigen-specific T-cell receptor complexT-cell receptor-CD3-peptide-MHC complex

The target is engaged by drugs to either redirect T-cell cytotoxicity against specific cells (e.g., tumor cells) by bridging the TCR-CD3 complex to a target antigen/MHC, or to modulate T-cell signaling and activation for immunosuppression [3, 5].